FSD Pharma Announces Investor Relations Agreement with IR Agency LLC

FSD Pharma Inc. (NASDAQ: HUGE), a biopharmaceutical company, has entered into an investor relations services agreement with IR Agency LLC. The agreement, effective May 22, 2024, aims to enhance communication between FSD Pharma and the financial community.

Under the terms of the agreement, IR Agency will undertake various tasks including creating Company profiles, media distribution, and building a digital community for a fee of C$335,699 (USD $245,000). The service period will commence on May 28, 2024, and last for one month.

IR Agency operates independently from FSD Pharma, with neither the Agency nor its principals holding any equity interest in the Company's securities. Rafael Pereira from IR Agency will manage the investor relations services.

FSD Pharma, through its subsidiary Lucid Psycheceuticals Inc., is focused on developing treatments for neurodegenerative and metabolic disorders. The company also holds a portfolio of strategic investments via its wholly-owned subsidiary, FSD Strategic Investments Inc.